NextCure, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
NextCure, Inc. received notice of failure to satisfy continued listing standards (Item 3.01). The company is a small-cap biotech ($12.6M market value) with no specific details provided in this filing regarding remediation timeline, specific non-compliance rule violated, or required actions. The filing is dated November 20, 2026, with period of report November 16, 2026.
Why this rating
Delisting is existential threat to small public company; would destroy market liquidity, valuation, and ability to raise capital. Dire for $12.6M-cap firm.
Extracted items
Tradability signal
NO TRADE
No trade: negative news, but this cell's evidence is too weak. Similar past filings (34 in this cell) moved -1.59% in the called direction over 4 hrs; shrunk for sample size that's a -0.91% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $7.08 ▲ 4.42% | at our read · unknown $6.78 | +10 min · unknown $6.78 ▲ 0.00% | +30 min · unknown $6.78 ▲ 0.00% | +1 hr · unknown $6.60 ▼ 2.65% | +4 hrs · unknown $6.73 ▼ 0.74% |
The stock had already moved -4.24% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.